Morari has developed a chemical-free wearable patch which allows men to enhance or improve sexual performance.
Maple Grove, MN, USA
One Liner
One Liner
Morari has developed a chemical-free wearable patch which allows men to enhance or improve sexual performance.
What Problem We are Solving
Problem
Premature ejaculation (PE) is the most prevalent male sexual dysfunction, estimated to affect 30% of men worldwide. With a higher incidence than erectile dysfunction (ED) or an enlarged prostate, PE represents a large global market opportunity. PE can be a serious quality of life issue. Most men don’t consult a doctor and doctors lack meaningful treatment options. The impact of PE on partners can be significant. The company’s market research discovered that many partners express disappointment, helplessness, frustration and unfulfilled feelings when their partners experience PE.
In the absence of PE, an additional 40% of men would prefer to last longer.
About Us
About Us
Morari has developed a chemical-free wearable skin patch for the treatment of premature ejaculation (PE). PE is the most prevalent male sexual dysfunction, estimated to affect 30% of men worldwide. With a higher incidence than erectile dysfunction (ED) or an enlarged prostate, PE represents a large global market opportunity. The company has completed proof of concept testing, developed a Bluetooth enabled prototype, completed an early feasibility study and has been issued one patent and filed several others for a wearable treatment solution.
Prior to penetration, a reusable electronics module is attached to a single-use patch. The patch is placed in the perineum which is the area between the scrotum and anus. The patch is worn during intercourse and disposed of after an ejaculation has occurred. The patch contains elements that, when activated, interferes with the nerve signals from the penis to the brain to delay an ejaculation.
Venture Highlights
Highlights
Highlights
A unique product in a $37B global sexual health and wellness market
Issued one patent and have filed for several others
Revenue projected to reach $25M by 2025 (not guaranteed)
Winner of Proctor and Gamble Innovation Challenge
Winner of Walleye Tank
Winner of best start-up award at 2021 Sex Tech Summit
Graduate of the gBETA Medtech Accelerator program
Semi-finalist in 2022 Minnesota Cup
Received Minnesota Innovation Grant Award
Global media buzz includes: Daily Mail, CNET, Men’s Health, Forbes, and the Jimmy Kimmel Live show: https://youtu.be/ViKog6Jubt4
Business Model
Business Model
Morari will launch its first product, Mor, via a direct-to-consumer approach to include creating an e-commerce site. Customers can place orders on a dedicated product landing site and then discreetly receive product which will be inventoried and shipped via an established fulfillment center.
This gives Morari a unique opportunity in a giant global sexual health and wellness market. We are planning to do the same for the PE market as Viagra did for the erectile dysfunction industry all those years ago.
Competitive Advantage
Quote
To date there is no wearable product available that has been clinically validated. There have been
attempts to treat PE through a variety of methods to include physiological/behavioral counseling, drug treatment, topical local anesthetics, cryoablation and radio frequency. Although there is no current FDA approved/indicated drug for PE, off label pharmacological treatment remains a first line treatment with an estimated market size of $1.5 Billion.
Psychological - Estimated PE Market Share is less than 5%
Start-stop and squeeze technique
Benefits are short lived
Sprays/Creams – Estimated PE Market Share of 75%
Takes time to be effective and affects spontaneity
May cause numbness for partner
Can be messy
Drugs – Estimated PE Market Share of 20%
Antidepressants (SSRIs) that are used off label for PE
Requires prescription
Side effects include weight gain, nausea, dry mouth, headache and loss of sexual desire
A future competitor will be Virility Medical. Our Key differentiators against Virility Medical will be:
1. Targeting nerves vs. muscle
2. DTC vs. direct-to-physicians
3. Reusable and rechargeable electronics module
Revenue
Revenue To Date
N/A
MRR
N/A
Revenue YTD
N/A
Burn Rate
$120K
Users
Total Users
N/A
Total Users (Past 30 Days)
N/A
Daily Active Users
N/A
Monthly Active Users
N/A
Total Paying Users
N/A
MoM Growth Users
N/A
Organic Traffic %
100%
Customer Costs
CAC
N/A
LTV
N/A
Churn
40%
Margins
65%
Go-To Market Strategy
Business Strategy
Once FDA clearance has been achieved and product inventory in place, Morari will sell the product through a new dedicated online website. To execute this, the company will initially use an existing e-commerce platform such as shopify.com to take and fulfill orders. The company will execute a soft launch for a period of 3 months before expanding to other markets. This soft launch approach will allow the company to ensure that all aspects of the launch to include order entry, fulfillment and shipping are working as expected. In addition, the soft launch will allow the company to gather important data related to order trends, customer profile and product performance. Following the 3-month soft launch, the company will expand to other metropolitan areas. The regional launch approach will allow us to be more selective and targeted in our launch rollout giving us data that can help with future execution vs. a national launch at the beginning.
To execute the launch, the company will be looking for key social media channels and influencers that have large followings to help with the awareness. These influencers will include talk show hosts, athletes, politicians, celebrities and/or musicians. Another opportunity for awareness building will be at conferences such as the Consumer Electronic Show (CES). The CES meeting now allows sexual tech products to exhibit along with other consumer products.
As awareness and sales for the Morari patch grows, the company expects that large retailers will be interested in offering the product via their online channels. The company will focus on large retailers such as Target, CVS, Best Buy and Walmart. As these retailers have begun to offer a diverse line of sexual wellness products in their stores and online, the company believes that the Mor patch aligns well with many of the existing sexual health offerings on large retailers.
The intention of the company is to work through a reputable supplier such as Church and Dwight where an existing relationship exists. In addition, the company has made inroads with online retailers that have significant distribution. Amazon, HIMS and Roman are all options the company is considering. Initially, though, the company will be cautious as it will want to ensure that the Morari brand is front and center and, for some of the online retailers, a white label product will be required. There is an option to license the product but that may be dependent on market receptivity.
There have been multiple attempts to treat PE through a variety of methods to include physiological/behavioral counseling, drug treatment, topical local anesthetics, cryoablation and radio frequency.
To date there is no chemical-free wearable product option available to consumers. Although there is currently no FDA approved/indicated drug for PE, off-label pharmacological treatment remains a first line treatment with an estimated market size of $900M.
Key companies either serving the PE market or broader sexual health and wellness sector today include Church & Dwight, Reckitt Benckiser, Roman, HIMS and Absorption Pharma. Virility Medical is an Israel based company who is working on a similar approached using a wearable product that targets muscle versus nerves. We will continue to follow Virility Medical closely as it represents the most similar competitive product threat.
We are open to meeting up to grab a coffee, or just to chat.
We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!
